Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of Ruxolitinib (RUX) for myelofibrosis (MF)-related splenomegaly

Trial Profile

A clinical study of Ruxolitinib (RUX) for myelofibrosis (MF)-related splenomegaly

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2018 Results (n=199 patients with early and overt primary Myelofibrosis ) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 27 Jul 2018 New trial record
    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top